Skip to Main Content

Paper Details

An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.
Cancer Chemother Pharmacol
21
2013
AKT, CD31, HIF1, IGF-1, MM, MM lines, PCNA, PI3K, SF1126, Velcade, bortezomib, hematopoietic malignancies, human, human MM cell lines, human myeloma (MM, integrin, mice, multiple myeloma, myeloma, p-AKT, patient, patients, phospho, phospho-AKT, phospho-ERK, phosphoinositide-3 kinase, primary MM tumor, primary MM tumor cells, primary patient-, primary patient-derived MM tumor cells, tumor

Datasets

Release 1.2